Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
19 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Themis Bioscience GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Themis Bioscience GmbH - Product Pipeline Review - 2014', provides an overview of the Themis Bioscience GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Themis Bioscience GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Themis Bioscience GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Themis Bioscience GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Themis Bioscience GmbH's pipeline products Reasons to buy - Evaluate Themis Bioscience GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Themis Bioscience GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Themis Bioscience GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Themis Bioscience GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Themis Bioscience GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Themis Bioscience GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Themis Bioscience GmbH Snapshot 4 Themis Bioscience GmbH Overview 4 Key Information 4 Key Facts 4 Themis Bioscience GmbH - Research and Development Overview 5 Key Therapeutic Areas 5 Themis Bioscience GmbH - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Themis Bioscience GmbH - Pipeline Products Glance 9 Themis Bioscience GmbH - Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 Themis Bioscience GmbH - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Themis Bioscience GmbH - Drug Profiles 11 Vaccine for Chikungunya 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 Vaccine for Dengue 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Vaccine for Yellow Fever 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Themis Bioscience GmbH - Pipeline Analysis 15 Themis Bioscience GmbH - Pipeline Products by Molecule Type 15 Themis Bioscience GmbH - Recent Pipeline Updates 16 Themis Bioscience GmbH - Locations And Subsidiaries 17 Head Office 17 Appendix 18 Methodology 18 Coverage 18 Secondary Research 18 Primary Research 18 Expert Panel Validation 18 Contact Us 19 Disclaimer 19
List of Tables Themis Bioscience GmbH, Key Information 4 Themis Bioscience GmbH, Key Facts 4 Themis Bioscience GmbH - Pipeline by Indication, 2014 6 Themis Bioscience GmbH - Pipeline by Stage of Development, 2014 7 Themis Bioscience GmbH - Monotherapy Products in Pipeline, 2014 8 Themis Bioscience GmbH - Phase I, 2014 9 Themis Bioscience GmbH - Preclinical, 2014 10 Themis Bioscience GmbH - Pipeline by Molecule Type, 2014 15 Themis Bioscience GmbH - Recent Pipeline Updates, 2014 16
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.